Evidence map›Paper›PMID 40387336›Full record

GuidelineAmerican journal of respiratory and critical care medicine2025

Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement.

Anna J Podolanczuk, Gary M Hunninghake, Kevin C Wilson, Yet H Khor, Fayez Kheir, Brandon Pang, Ayodeji Adegunsoye, Gretchen Cararie, Tamera J Corte, Jim Flanagan and 30 more

Erratum issuedAbstract readPractice GuidelineReview
In one paragraph

Guideline in American journal of respiratory and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors.

Anna J PodolanczukORCID 0000-0002-9559-1485
Gary M HunninghakeORCID 0000-0001-9782-2841
Ayodeji AdegunsoyeORCID 0000-0002-7015-9610
Gretchen Cararie
Jim Flanagan
Gunnar GudmundssonORCID 0000-0002-7251-8322
Stephen M HumphriesORCID 0000-0002-5113-4530
Melanie KonigshoffORCID 0000-0001-9414-5128
Jonathan A KropskiORCID 0000-0002-8923-1344
Fernando J MartinezORCID 0000-0002-2412-3182
Sydney B Montesi
Ivan O Rosas
Margaret L SalisburyORCID 0000-0001-8217-6955
Mary M Salvatore
Marina Vivero
Marlies WijsenbeekORCID 0000-0002-4527-6962
Christopher J RyersonORCID 0000-0003-1049-393X

Funding

Project 4: Defining the Molecular Natural History of Early and Progressive Pulmonary FibrosisP01HL172729 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Nicholas Eli Banovich · 2024 to 2026
$11.2M
Clinical Genetics and Screening for Pulmonary FibrosisR01HL130974 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GARY MATTHEW HUNNINGHAKE, Benjamin Alexander Raby · 2016 to 2026
$10.0M
Genetic and Genomic Characterization of the Occurrence and Progression of Interstitial Lung AbnormalitiesR01HL135142 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MICHAEL H. CHO, GARY MATTHEW HUNNINGHAKE · 2017 to 2026
$7.7M
Interstitial Lung Abnormalities: Defining the Phenotype, Causes, and Consequences.R01HL111024 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNNINGHAKE, GARY MATTHEW · 2013 to 2022
$6.4M
Genes and Transcripts that Interact with MUC5B in Pulmonary FibrosisR01HL149836 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI CLOUTHIER, DAVID E., SCHWARTZ, DAVID ALBERT · 2020 to 2023
$3.0M
Proteomic Profiling of Idiopathic Pulmonary Fibrosis Progression TrajectoryR01HL169166 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2023 to 2026
$2.7M
Prognostic Biomarker Development in Progressive Fibrosing Interstitial Lung DiseaseR01HL166290 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2024 to 2026
$2.2M
Reconceptualizing Disease Progression in Pulmonary FibrosisR01HL179065 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Margaret Louise Salisbury · 2025 to 2026
$1.5M
Vascular Leak and Outcomes in IPFK23HL150331 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MONTESI, SYDNEY · 2020 to 2024
$887k
Defining the biologic and physiologic trajectory of presymptomatic through advanced pulmonary fibrosisR56HL166941 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SALISBURY, MARGARET LOUISE · 2023 to 2023
$768k
NHLBI NIH HHS K23 HL150331NHLBI NIH HHS P01 HL172729NHLBI NIH HHS R01 HL111024NHLBI NIH HHS R01 HL130974NHLBI NIH HHS R01 HL135142NHLBI NIH HHS R01 HL149836NHLBI NIH HHS R01 HL166290NHLBI NIH HHS R01 HL169166NHLBI NIH HHS R01 HL179065NHLBI NIH HHS R56 HL166941Wellcome Trust
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lung Diseases, InterstitialDiagnosis, DifferentialHumansLungSocieties, MedicalTomography, X-Ray ComputedUnited Statescomputed tomographyinterstitial lung abnormalities (ILA)interstitial lung disease (ILD)pulmonary fibrosisscreening

Identifiers

PMID40387336
PMCPMC12264694

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.